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Hypothyroidism is common throughout the world and readily diagnosed with thyroid
function tests. Management should be straightforward but appears not to be the case.
Thyroid hormone replacement with levothyroxine monotherapy is the standard treatment
which is effective in the majority of cases. However, 10–15% of patients established
on levothyroxine do not feel their health is entirely restored and some patients prefer
the addition of liothyronine. Proponents of liothyronine argue that the ratio of T3 and
T4 hormones is substantially altered on T4 monotherapy and therefore both hormones
may be needed for optimal health. This remains controversial as clinical trials have not
demonstrated superiority of combination therapy (levothyroxine and liothyronine) over
levothyroxine monotherapy. There is now a pressing need for further studies and in
particular randomized controlled trials in this area. To help design and facilitate dedicated
trials and better understand thyroid hormone replacement, this review summarizes the
evidence where there is established knowledge and agreement (knowns) and areas
where research is lacking (unknowns). Agreements include the extent of dissatisfaction
with levothyroxine monotherapy, biases in testing for hypothyroidism and prescribing
levothyroxine, as well as variable thresholds for prescribing levothyroxine and challenges
in liothyronine dosing. The review will also highlight and summarize the unknowns
including the long-term safety profile of liothyronine, and potential biomarkers to identify
individuals who might benefit most from combination therapy.
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INTRODUCTION
Hypothyroidism is common throughout the world and particularly affects females (1). It is readily
identifiable and treatable, but if untreated or poorly managed can have profound adverse effects
(1, 2). Levothyroxine (LT4) is the current standard treatment although liothyronine (LT3) and
desiccated thyroid extract (DTE) are also used (2, 3). Prior to the 1970’s both combination thyroid
hormone replacement (LT3 + LT4) and DTE were widely prescribed (4). The discovery that T4
is largely activated to T3 outside of the thyroid within target tissues (5) and concerns regarding
dosing and stability of FT3 profiles in patients on LT3 or DTE have made LT4 the standard of care
for nearly 50 years. Thyroid hormone replacement is now an important global public health issue
and as at present, LT4 is the most commonly prescribed medication in the USA and the third most
commonly prescribed in the UK (2).
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The diagnosis and monitoring of hypothyroidism is largely
biochemical and undertaken using easily available laboratory
thyroid function tests. The inverse relationship between thyroid
hormone and the pituitary derived hormone, thyrotropin (TSH)
has lead to TSH becoming the accepted marker of thyroid status
(6) and the goal of treatment is therefore to normalize TSH
levels (2). Whilst such an approach appears at first instance to
be straightforward several issues have been raised in recent years
which necessitate further research. These are fundamental and
relate to the diagnosis, treatment, and monitoring of thyroid
function. As a result, calls have been made that the focus on
TSH rather than symptom relief should be re-assessed (7). A
joint consideration of TSH, patient symptoms, and a more
personalized approach may therefore be required to address
the recent surge in patient complaint rates (7). Indeed thyroid
hormone, once thought to be the easiest hormone to replace, has
become very controversial, with patient groups challenging the
assumptions of endocrinologists.
The most pertinent issue is that there are widespread reports
of dissatisfaction with LT4 replacement (8) estimated at 10–15%
of patients (2, 9). It is difficult to assess the extent to which this
reflects dissatisfaction in the general population as undergoing
thyroid function testing itself is a predictor of psychological
morbidity (10). This effect may be further exaggerated by the
dramatic increase in thyroid function testing and initiation of
LT4 at lower TSH thresholds in recent years (11, 12).
LT4 monotherapy results in individuals having relatively
lower FT3 and higher FT4 levels than individuals with an
intact, undisturbed, hypothalamopituitary-thyroid (HPT) axis
(13), but the clinical relevance of this finding is controversial (14).
Consistently many patients (∼20%) may be apparently “over-
replaced” with LT4 as evidenced by a low or suppressed TSH
(11, 15, 16). There is evidence that a lower TSH can result in
greater patient satisfaction (17), but also greater long term risks
(18). In the UK in particular, due to widespread concern and
media coverage over recent large increases in costs of LT3 and
access to treatment (19) more patients are now aware of and
desiring combination LT3:LT4 replacement. Increased awareness
and self-medication with LT3 has also been observed in Denmark
(20) and the USA (8). Four systematic reviews/meta-analyses
of trials of combination LT3:LT4 replacement found no clear
benefit of combination therapy over LT4 monotherapy (21–24).
However, some of the key limitations of these trials (discussed
further below) included small sample sizes, variable quality in
outcomes assessed, the use of only once daily (“pulsatile”) rather
than slow release T3 dosing and the acceptance that feedback to
TSH is the same with all forms of thyroid hormone replacement
resulting in potential for dose titration errors. Furthermore, there
is recent evidence that T4 inhibits the deiodinase that converts T4
to T3 in target tissues, with the potential to result in paradoxically
reduced levels of intracellular T3 when there is a high circulating
T4/T3 ratio (25).
Based on this uncertainty regarding the benefit of LT3,
current European Thyroid Association guidance (26) recognizes
that LT4 is the treatment of choice but recommends that a
3-months trial of LT3 could be considered in patients with
persistent unexplained symptoms despite good compliance.
Likewise, a British Thyroid Association position statement also
endorses LT4 as the treatment of choice but acknowledges that
a trial of combination therapy could be warranted in patients
who have unequivocally failed to respond to LT4 following a
discussion with the patient of the uncertain risks and benefits
of combination therapy (27). Whilst current American Thyroid
Association guidance (28) indicates a trial of LT3 can be
considered in carefully selected patients it also highlights no
consistent superiority of combination LT3:LT4 therapy. DTE
was not endorsed in either the European, British, or American
guidelines (26–28).
Set against the uncertain benefits of combined LT3:LT4
therapy a balance has to be made against the potential for
adverse consequences of using LT3. The lack of clarity in
both these areas results in difficult decisions for patients and
clinicians. Equally, maintaining the status quo is not desirable
given the dissatisfaction that exists with LT4 monotherapy
and the numbers of patients being over-replaced on current
monitoring with TSH. A substantial number of patients
seek to try LT3 monotherapy or other preparations such as
DTE and have sought to source their therapy themselves
(19). Failure of endocrinologists to engage sufficiently with
these patients may place individuals at unnecessary risk
of over-replacement.
Taken together there is a pressing need for further randomized
controlled trials in this area, as well as research into longer
acting LT3 preparations, better markers which predict tissue
thyroid status, better assessments of treatment outcomes, and
improved knowledge of the benefit-risk profile of long-term
combination LT3:LT4 therapy. A review of the current evidence
for combination thyroid hormone replacement with an overview
of future research directions is therefore timely. We will
summarize and identify areas of existing knowledge and research
agreement (the knowns) as well as areas where data are more
urgently needed (the unknowns).
THE KNOWNS
Serum T4, Not Serum T3 Is the Main
Source of T3 Within Cells
In mammals, the majority of active thyroid hormone
(T3) within cells is derived not directly from T3 in the
circulation, but indirectly from T4, via the action of the
D2 deiodinase (29, 30). The concentration of circulating
T4 is about five times higher than T3 and it is the
circulating T4 rather than T3 that serves as the main
source of thyroid hormone for the body (5). In addition a
proportion of serum T3 is also derived from serum T4 (5).
These considerations have been used as a key theoretical
argument against the use of LT3 in the management
of hypothyroidism.
However, serum thyroid hormone levels may not entirely
reflect intracellular thyroid hormone status. Via variation
in uptake, activation and metabolism of T4, cells can
modulate intracellular T3 levels independently of circulating
thyroid hormone levels. Downstream control by thyroid
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hormone transporters such as MCT8 and MCT10, the
deiodinases (DIO2,DIO3), and transcription co-factors locally
modify thyroid hormone bioavailability and action at the
intracellular level. The potential for dichotomy between
serum thyroid hormone levels and intracellular action
is dramatically illustrated in reports of individuals with
rare mutations in the MCT8 transporter (Allan-Herndon-
Dudley syndrome) or the thyroid hormone receptor alpha
(present in many tissues but not the hypothalamus/pituitary)
(31, 32). Here, marked tissue-specific hypothyroidism is
seen with dramatic effects on bone and brain development
despite “normal” or even raised serum thyroid hormone
levels (31, 32). The effects of more common variants are
less clear.
At the same time evidence has been accumulating of
tissue-specific regulation of thyroid hormone contents
in tissues via differential expression of thyroid hormone
transporters and iodothyronine deiodinases (29, 33). It
has been hypothesized that LT4 monotherapy may not
restore intracellular T3 levels in the brain in all patients
and this may explain the dissatisfaction some patients have
on LT4.
There Is Dissatisfaction in Individuals With
Hypothyroidism Who Are on LT4
Monotherapy
Even with normalization of TSH, patients may still complain
of symptoms overlapping with overt hypothyroidism such as
lethargy, sleepiness, memory problems, inability to concentrate,
and process information (“brain fog”), feeling cold and
weight gain (2). Symptoms consistent with the presence of
hypothyroidism are very non-specific and cannot be used
to differentiate those with hypothyroidism from euthyroid
controls (34). Dissatisfaction with LT4 monotherapy is not
a new issue. Even in the early 1970’s when traditionally
higher treatment doses (150 mcg of LT4 and 45 mcg of
LT3) were used and treatment initiated at more advanced
disease stages, it was recognized that a subset of individuals
required LT3 to restore health (35). This would suggest
that dissatisfaction is not simply a consequence of persistent
symptomatology due to minor thyroid function abnormalities.
It is a consistent finding that patients on LT4 replacement
even with a normal TSH display significant impairment in
psychological well-being compared to controls of similar age
and sex (36–39). Whilst this could, at least in part be
attributed to disease misclassification (not treating co-existing
depression) or confounding it could also indicate that in a
proportion of patients there is imperfect replacement with
LT4 alone.
For cohort studies and clinical trial design, it is worth
considering that standard assessments such as the General
Health Questionnaire and Hospital Anxiety and Depression
Score may not capture effectively all the symptoms leading
to dissatisfaction. Thus, more disease-specific outcome
measure such as THYPRO (40) may provide more robust
outcome assessment.
Patients Who Have Their Thyroid Function
Tested Are Growing in Number, but Are Not
Entirely Representative of the General
Population
There has been a steady increase in thyroid function testing
in the last two decades (1, 11, 12, 41). In keeping with this,
cohort data from Norway has identified that the prevalence
of untreated hypothyroidism is 0.1% representing an 84%
fall from the 1990s (42). Individuals who have their thyroid
function checked are more likely to be female, aged over
60 (43), have higher psychological morbidity (10), but
do not appear to have increased rates of hypothyroidism
compared to the general population (10). In the UK, the
three most common reasons for thyroid function testing
that led to a prescription of LT4 are depression, fatigue and
weight gain (11). This suggests—perhaps not surprisingly—
that individuals with these complaints are preferentially
selected for testing for thyroid function and since subclinical
hypothyroidism is common (especially in females over
60 where rates approach 10%), a “co-incidental” finding
of subclinical hypothyroidism with these symptoms will
commonly occur.
Importantly, these potential selection biases will need to
be taken into account in cohort studies. Symptoms at initial
levothyroxine prescription may need to be considered by
selection criteria or minimization depending on the outcome
measure used.
Patient Characteristics Influence Current
Prescribing Practice and Treatment Course
Individuals with only borderline abnormalities in TSH are
increasingly being started on LT4 (11, 12, 44). It appears
that thresholds for levothyroxine initiation differ according to
patient symptoms at presentation. For example, individuals with
tiredness or depression had levothyroxine initiated at lower TSH
thresholds than those who had their thyroid function checked
as part of general screening (11). This is pertinent as it is
well-established that thyroid-related patient complaints overlap
with a plethora of non-specific symptoms which may be caused
by other conditions (11, 45, 46). Future trials of combination
thyroid hormone replacement need to have inclusion criteria
which take into account the patient’s thyroid status at initiation
of levothyroxine. For instance, individuals with non-specific
symptoms and borderline or normal thyroid function (prior to
treatment)may have little to gain from either LT4 or combination
LT3:LT4 therapy (47, 48).
Being female and having higher net family income are
predictive factors for receiving LT4 (49) although it is not clear
from this data if this was driven by increased thyroid function
testing in these groups. In the UK there is a 49-fold variation in
the number of LT3 prescriptions per 1,000 LT4 prescriptions by
local prescribing region (19). A substantial driver of this has been
the dramatic price rise in LT3 in the UK. Crucially, patients in
deprived areas were much less likely to receive LT3, even before
the price rises, and this has become more dramatic following
prescription cost changes. Cohort studies looking at long term
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outcomes of LT3 therapy will need to consider social class bias
when assessing these outcomes.
Whilst data on the demographics of patients on LT3 are
lacking, insights may be attained from studying cohorts of
patients on LT4. Individuals treated with LT4 for primary
hypothyroidism in the UK were more likely to develop
a suppressed TSH following treatment if they originally
presented with depression, tiredness or fatigue (11). Women
and individuals with a TSH of <4.0 mU/l at index prescription
were also more likely to develop a suppressed TSH (11) on
LT4 while older individuals and those with cardiovascular risk
factors were less likely to (11). It is not unreasonable to suggest
that if these symptoms have persisted despite supra-physiological
doses of LT4, then these individuals may be more likely to
receive a prescription for LT3. This creates two issues, (i) a
potential bias in individuals who receive LT3 and (ii) inclusion
into LT3 trials of individuals with borderline thyroid function
(including top of the normal range) who become classified as
hypothyroid because they are receiving LT4. In such individuals
LT3 may be of questionable benefit thus negating a treatment
response. There is therefore a compelling argument that in
the inclusion/exclusion criteria setting, an index TSH threshold
before initial LT4 prescription should be used; a TSH threshold
between 6.0 and 10.0 mU/l at index LT4 prescriptionmay balance
the competing priorities of ease of recruitment and ensuring the
presence of sufficient thyroid disease.
Patients on Levothyroxine Replacement
Do Not Have “Normal” Thyroid Function
Patients treated with levothyroxine to achieve normal serumTSH
values typically have serum triiodothyronine (T3) concentrations
in the reference range but with increased levels of T4 resulting
in a significantly increased T4/T3 ratio (13, 50). In individuals
studied before and after thyroidectomy absolute serum T3
levels change little once TSH is normalized (50, 51), but
in individuals with subclinical hypothyroidism where there is
increased deiodinase activity and T3 production, treatment with
T4 alone results in a fall in absolute T3 serum levels in addition
to the rise in T4/T3 levels (52).
Studies of patients established on levothyroxine also reveal
that the relationship between TSH and FT3 disassociates on
LT4 monotherapy particularly in athyreotic individuals (13, 50,
53). Supra-physiological levels of FT4 are actually required to
normalize serum FT3 levels (50). In animals LT4 monotherapy
was unable to restore euthyroidism at the tissue levels despite
bringing TSH within its reference range (54) and supra-
physiological doses were also required to normalize tissue T3
levels (54). In a small number of patients with goiter who received
levothyroxine before thyroidectomy, a 33% increase in LT4 dose
was required after thyroidectomy to maintain pre-surgical TSH
levels (51) but a clear reduction in FT3 was not observed in the
same patient before and after thyroidectomy.
It has been reported in cell lines that T4 inhibits the activity
and promotes the destruction of the key deiodinase enzyme,
D2 that activates T4 to T3 within cells (55). This results in
“autoregulation” that serves to protect cells from excess T4, but
also to increase local T3 production where T4 levels are reduced.
If this mechanism occurs in vivo, treating subclinical hypothyroid
subjects with T4 alone paradoxically may make their tissue
hypothyroidism worse. Note that in the cell line studies, pituitary
cells were less prone to such “autoregulation,” suggesting that
TSH would still be effectively suppressed with T4 monotherapy
despite inhibition of T3 generation within peripheral tissues.
As result, paradoxical reduction in local T3 generation on T4
alone would be expected to occur despite normalizing or even
suppressing TSH levels. This is likely to be less of a concern in
profoundly hypothyroid individuals, in whom any increase in T4
is likely to contribute positively to the generation of intracellular
T3 as levels are so low, but result in “net deterioration” in
individuals who were initially only subclinically hypothyroid.
What is less clear is the extent of other regulators in the thyroid
hormone pathway, including FT3 levels and transport. Taken
together it is plausible that multiple “hits” are required to induce
substantial tissue hypothyroidism, making the percentage of
people who will clearly benefit from LT3 difficult to predict.
In support of this hypothesis, a recent large cohort study
confirmed that individuals on LT4 had 15–20% lower T3:T4
ratios on LT4 than healthy or matched controls (14). Prolonged
exposure to this different ratio appeared to have adverse health
outcomes as, LT4 treated individuals had higher a body mass
index despite lower calorie consumption, reported less physical
activity and were more likely to be taking antidepressants (14),
although confounding remains a possibility.
An additional factor is an individually tailored dose of T4 is
not widely used, although more mixed doses are being used e.g.,
100/125 mcg alternate days. It is also common to encounter a
subset of hypothyroid patients who require unexpectedly high
doses of T4 or who have erratic control. A variety of factors can
cause this including poor compliance, use of different brands,
impaired absorption secondary to gastro-intestinal pathology
(e.g., coeliac disease), use of other medications (e.g., iron
supplements) timing of medication (ingestion of caffeine around
the time of T4 will impair absorption) (56, 57). Repeated dose
changes and sub-optimal control will also reduce satisfaction
with T4. Novel T4 preparations including gel and elixir may
improve absorption (58) and may therefore improve satisfaction
with LT4 treatment.
Reliance on TSH Alone May Be
Problematic
Due to small changes in thyroid hormone levels resulting in
large TSH modifications, TSH has been the preferred diagnostic
test for hypothyroidism (6). However, this approach has been
challenged (7). Key issues include that its reference-interval
is not universally agreed and it is not usually adjusted for
other factors such as ethnicity and iodine status. Studies have
also identified in athyreotic rats treated with LT4 that the
brain, skeletal muscles and liver continue to exhibit markers
of hypothyroidism (25). In contrast, in the hypothalamus the
effect of T4 on downregulating D2 activity appears to be less
as discussed above, which might explain TSH normalization
despite tissue hypothyroidism elsewhere. This is important as it
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is perhaps unlikely therefore that TSH accurately reflects thyroid
hormone concentrations in all tissues and organs on T4 alone.
By contrast, chronic combination LT3:LT4 therapy was able to
normalize thyroid hormone dependent biological parameters in
the brain, liver, and skeletal muscle (25).
Restoring TSH to the reference-range has been adopted as
the goal of thyroid hormone replacement. However, TSH may
not be corrected to an individual’s own reference range. Genetic
variation in PDE8B is robustly associated with TSH levels (59–
61) but this relationship is lost in individuals on LT4, thus
indicating that whilst TSH is normalized on LT4 therapy this
may not be to an individual’s genetic set-point (60). It is well-
established that intra-individual variation in thyroid hormone
levels is much narrower than inter-individual variation (62)
and that thyroid hormone levels in healthy adult individuals
are largely genetically determined (59, 61). Thus, individuals
could have thyroid function measurements within the normal
laboratory reference range which are “abnormal” for them. The
clinical implications of this remain unclear, but are pertinent
in individuals on thyroid hormone replacement who may attain
blood thyroid hormone levels within the reference-range but not
at their genetically determined set-point (60). In practice, severe
clinical presentations of hypothyroidism have been documented
in individuals with only mildly elevated TSH levels (63). Given
an individual has a narrow genetically determined set point of
thyroid function (62) the long-term health consequences are
unclear and merit further study.
Current LT3 Dosing Strategies Do Not
Replicate T3 Levels in Euthyroid Individuals
FT3 levels show a substantial peak 2–4 h after a dose and wear
off after 12 h in individuals on a single daily dose of LT3.
Similar profiles on FT3 are observed in hypothyroid patients
on combination LT3:LT4 therapy (64), LT3 monotherapy (65,
66), and also euthyroid individuals taking LT3 (67). These
profiles are markedly different from euthyroid individuals not
on thyroid medications. In particular the peak FT3 level is
often substantially above the reference-range. Long-acting T3
preparations are in development and may be the key here (68).
Long-acting preparations make it easier to monitor dosing, as it
possible to assess 24 h T3 exposure from a single measurement.
In addition, TSH levels under these state T3 (and T4) conditions
are also more likely to be a true reflection of thyroid status
compared to the feedback effects of “pulsatile” T3 on TSH levels
(66)—see “unknowns” below. Normalization of tissue thyroid
status in murine studies was achieved using slow release pellets
of T4 and T3 (25). It is worth noting that in contrast to LT3 novel
LT4 formulations including gel and elixir are available in most
but not all countries (58).
The ratio of LT3:LT4 is also of paramount importance. Given
the majority of circulating T3 comes from peripheral conversion
of FT4 to FT3, a secretion ratio of FT4:FT3 in healthy individuals
is ∼14:1 (69, 70). ETA guidelines (26) suggested three possible
methods for calculating LT3 and LT4 doses to give a T4:T3 ratio
between 13:1 and 20:1 which is close to normal thyroid hormone
secretion, however this ratio is generally lower than those used in
clinical trials to date (70). Using these recommended ratios (26)
a patient on 100 mcg of LT4 would require between 4 and 6 mcg
of LT3 which would be impractical to deliver in split doses with
current LT3 formulations.
LT3 dosing is also critical when assessing potential benefits. It
is worth noting that one of the key early studies which favored
LT4 monotherapy in terms of patient preference over LT3:LT4
combination treatment (71) used up to 60 mcg of LT3 a day.
Anxiety and palpitations were common at this high dose which
may explain why LT4 monotherapy was preferred in this study.
Combination LT3:LT4 Therapy Has Not
Demonstrated Clear Superiority Over LT4
Monotherapy in Clinical Trials
To date there have been at least 13 randomized controlled trials
(RCT) comparing efficacy of combination LT4:LT3 therapy vs.
LT4 monotherapy (70). Four systematic reviews/meta-analyses
(21–24) of these trials of combination LT3:LT4 replacement
found no clear benefit over LT4 monotherapy in terms of mood,
health-related quality of life, or cognitive function. This data
has been taken to suggest that at the population level there
is no benefit of using combination therapy over monotherapy.
However, in no study to date has physiological replacement been
achieved (59). It is noteworthy that Wiersinga et al. (26) reviewed
the five cross-over trials (72–76) and identified that despite
adequate blinding 48% of all hypothyroid patients preferred the
LT3:LT4 combination therapy, 27% preferred LT4 monotherapy,
and 25% had no preference. Furthermore, studies in which
low or low normal levels of TSH were achieved frequently
reported benefit (73, 77–79). Although this has been taken
to suggest “overdosing,” the lower TSH levels may relate to
the unphysiological nature of the T3 replacement as discussed
above. Potentially more robust disease-specific patient reported
outcomes such as THYPRO are now available (40). Overall
seems reasonable to assume that combination therapy cannot be
assumed to have no advantages over monotherapy until a well-
designed long-term trial of physiological combination treatment
with a sustained release preparation or three times daily dosing of
FT3 has been conducted. Such a trial ideally would be adequately
powered to assess specific subsets of patients e.g., those with
symptomatic disease, established hypothyroidism, and genetic
predispositions such as variation in DIO2 (80).
UNKNOWNS
Serum TSH May Be Determined
Predominantly by Circulating T4, Not T3
While the complex inverse relationship between the thyroid
hormones and TSH (6) is well-established, the relative
contribution of FT4 and FT3 in regulating TSH levels is
less clear. FT4 may have a greater effect on TSH than FT3
(81). As a result, feedback on serum TSH and its production
may be predominantly determined by circulating T4, not T3.
This becomes highly relevant when the balance between T4
and T3 in the circulation is perturbed by replacement with
T4 monotherapy, as is standard in endocrine practice. Thus,
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TSH levels may appear to be suppressed more easily on LT4
monotherapy. More research is needed to clarify the relative
contributions of LT4 and LT3 therapy on TSH levels.
The Effect of Short Acting LT3 May Have a
Disproportionate Effect on TSH
T4 is slowly metabolized with a serum half-life of several days.
As a result, once daily dosing results in <20% variation in T3
levels over 24 h. In contrast, T3 has a shorter half-life, and even
2–3 times a day dosing results in substantial fluctuation in T3
levels over 24 h (64). This variation increases with the proportion
of T3 in the replacement formulation when combination T3/T4
therapy is used. The effect of this is unclear, but one potential
consequence is that spikes of T3 may have a greater suppressive
effect on TSH than for the same area under the curve for T3.
The Role of Circulating T3 Is Unclear
Circulating T3 appears to have a different role in physiology than
circulating T4. This is illustrated by several observations, some
familiar to endocrinologists and some less familiar. First, even
during profound hypothyroidism (e.g., T4 < 5.0 pmol/L, TSH
> 20 mU/L), T3 is almost always maintained in the reference
range. Second, by contrast, during acute illness T3 falls rapidly
whereas T4 is maintained, or may even rise (82). Third, 25%
of children under 7 years of age have T3 levels above the adult
reference range, with a normal TSH (81). Fourth, higher T3
levels in children (and adults) correlate with increased body mass
index (83). Consistent with this, children with higher T3 levels
have earlier onset of puberty (81). Mendelian randomization
studies suggest that in fact fat mass somehow causes an increase
in T3 levels, rather than vice-versa (83). Taken together, these
observations suggest that circulating T3 levels have a role in
signaling nutritional or health status to the brain, perhaps more
so than being a major source of T3 to tissues.
The Usefulness of SNPS in Predicting Who
Will Benefit From Combination Therapy Is
Unclear
Genetic variation in the deiodinases is associated with altered
thyroid function and adverse health outcomes (84). However,
effects have been modest and not consistently replicated.
Individuals with genetic variants in DIO2 (rs225014) (80)
and MCT10 (rs12885300) (77) have shown preference for
combination LT3:LT4 therapy with an additive effect (77).
However, these studies had limitations due to multiple testing
(80) and small sample size (77). Individual SNPs may have
poor discriminatory power in determining who might benefit
from LT3:LT4 combination therapy. Alternative strategies such
as a panel of single nucleotide polymorphisms or the use of
thyroid hormone metabolites or metabolomics may provide
better insight into tissue thyroid status. Metabolomic profiles
are likely to represent a unique method to assess thyroid status
as the metabolites released into the serum provide a fingerprint
of thyroid hormone action in tissues. Small studies have shown
FT4 concentrations are strongly linked to serum acylcarnitines
and phosphatidylcholines, indicating enhanced transport of fatty
acids to mitochondrion and subsequent β-oxidation (85). More
recently a larger study of urinary metabolites revealed positive
relations of alanine, trigonelline, and lactic acid with FT4 and
negative relations of dimethylamine, glucose, glycine and lactic
acid with TSH (86). To date the effect of FT3 on metabolomics
has not been studied. This is likely to be an important research
area with potential to identify new biomarkers related to
thyroid status.
There Is Limited Data About the Safety
Profile of Long-Term LT3 Therapy
An important argument against the widespread use of LT3 is the
lack of data on the safety of long-term use. Given the relatively
small number of patients using combination LT3:LT4 therapy
this is unlikely to be resolved soon. Most of the studies have
been of short duration and only one lasted a full year. A recent
observational study (87) of 400 patients on LT3 therapy (median
duration of therapy 10.9 years) did not identify an increased
risk of cardiovascular disease (HR 1.04 95%CI 0.70, 1.54), atrial
fibrillation (HR 0.91 95%CI 0.47, 1.75), or fractures (HR 0.79
95%CI 0.49, 1.27), after adjusting for age, despite lower levels
of TSH in “ever users” of T3 vs. “never users” (1.07 mU/l
vs. 2.08 mU/l, p < 0001). An increased risk of anti-psychotic
medication prescription was noted in T3 users, which may reflect
biases in individuals who receive LT3. It is also worth noting
that none of the 13 RCTs comparing combination therapy to
LT4 monotherapy showed any increase in adverse events in the
combination group, although follow-up was short ranging from
5 to 52 weeks (70).
It would nonetheless be prudent to have agreed monitoring
protocols in individuals on long-term LT3 therapy. Sensible
assessments would include pulse rate and rhythm, blood
pressure, andmood (in particular anxiety). Tests to be considered
will include ECG, echocardiograms, and DXA to assess bone
density. Having agreed standardized monitoring protocols,
ongoing regular assessments in patients on LT3 will be needed
to both address and monitor for potential safety concerns.
CONCLUSION
It has proved challenging when treating a proportion of patients
with hypothyroidism to ensure they are restored to optimal
health. This is perhaps surprising considering the high global
prevalence of this chronic condition (1). Although current
management practices may satisfy the majority of patients, they
remain sub-optimal. Key issues affect all stages of management
and include excessive thyroid function testing, variation in
threshold for treatment by presenting symptoms, widespread
over-replacement on LT4 as evidenced by suppressed TSH,
and inequality in access to LT3 (19). Using TSH alone to
make management decisions may not be effective for at
least a sub-group of patients (7). All these factors result in
challenging decisions and different priorities for patients and
their physicians (88, 89).
Given the importance of thyroid status for health (90)
and the substantial dissatisfaction with LT4 replacement (8)
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further research is urgently needed. There also needs to be
studies addressing alternative markers of tissue hypothyroidism
other than TSH, such as genetic markers, metabolites, and
metabolomicmarkers. In tandem there needs to be cohort studies
of existing patients on combination therapy to identify any
potential long-term health complications.
Clinical trials will need to factor in the following to have
the best chance of a meaningful result: (i) patient selection to
take into account symptoms at first diagnosis, TSH threshold at
LT4 initiation, co-morbidities including auto-immune diseases,
(ii) Near physiological LT3 therapy in the trials (multi-dosing
or long acting LT3) titrated to a physiological T4/T3 ratio
and a normal or low normal TSH, (iii) appropriate outcome
assessment such as THYPRO, (iv) sufficient power to detect
modest effects which would still be of substantial impact at
the population given the prevalence of hypothyroidism and
dissatisfaction with LT4 therapy, and (v) sufficient power to
detect treatment effects in subgroups, such as patients with the
DIO2 genotype.
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